Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Targovax ASA ( (GB:0RIS) ) is now available.
Circio Holding ASA has presented new data showcasing the significant advantages of its circular RNA circVec platform over current mRNA-based technologies. The findings, presented at major biopharma conferences, highlight the platform’s potential to enhance RNA durability and protein expression, opening up new therapeutic opportunities, particularly in cell and immune therapies. The promising results could transform existing AAV gene therapy standards and generate substantial interest from potential partners.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in circular RNA vector expression technology for next-generation nucleic acid medicine. Their proprietary circVec platform enhances and prolongs protein expression compared to traditional mRNA systems, with applications in genetic medicine, cell therapy, and chronic disease. Circio is also developing a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, currently in clinical trials for pancreatic and lung cancer, as well as multiple myeloma.
YTD Price Performance: -93.95%
Average Trading Volume: 23,211
Technical Sentiment Consensus Rating: Buy
Current Market Cap: NOK50.62M
Learn more about 0RIS stock on TipRanks’ Stock Analysis page.